Zevra Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Zevra Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-1.7%
Buyback Yield
| Total Shareholder Yield | -1.7% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
Nov 15
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ZVRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZVRA's dividend payments have been increasing.
Dividend Yield vs Market
| Zevra Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ZVRA) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (ZVRA) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate ZVRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZVRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ZVRA's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ZVRA has not reported any payouts.